Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-07-19
2011-07-19
Kim, Jennifer M (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252010, C544S237000, C548S366400
Reexamination Certificate
active
07981890
ABSTRACT:
A compound of the formula (I):wherein RHrepresents one or more optional substituents on the fused cyclohexene ring; R1is selected from H and halo; RNis selected from H and optionally substituted C1-10alkyl; and RC1and RC2are independently selected from H, R, C(═O)OR, where R is optionally substituted C1-10alkyl, optionally substituted C5-20aryl or optionally substituted C3-20heterocyclyl; RC1and RC2together with the carbon atom to which they are attached may form an optionally substituted spiro-fused C5-7carbocylic or heterocyclic ring.
REFERENCES:
patent: 3813384 (1974-05-01), Vogelsang et al.
patent: 4665181 (1987-05-01), Thomas et al.
patent: 4841047 (1989-06-01), Engel et al.
patent: 4912115 (1990-03-01), Bomhard et al.
patent: 5032617 (1991-07-01), Lee et al.
patent: 5041653 (1991-08-01), Lee et al.
patent: 5215738 (1993-06-01), Lee et al.
patent: 5556856 (1996-09-01), Engel et al.
patent: 5587384 (1996-12-01), Zhang et al.
patent: 5648355 (1997-07-01), Theoharides
patent: 5874444 (1999-02-01), West
patent: 5886178 (1999-03-01), Allen et al.
patent: 6197785 (2001-03-01), Jackson et al.
patent: 6340684 (2002-01-01), Napoletano et al.
patent: 6426415 (2002-07-01), Jackson et al.
patent: 6476048 (2002-11-01), Szabo et al.
patent: 6498160 (2002-12-01), Napoletano et al.
patent: 6514983 (2003-02-01), Li et al.
patent: 6514984 (2003-02-01), Watanabe
patent: 6635642 (2003-10-01), Jackson et al.
patent: 6677333 (2004-01-01), Seko et al.
patent: 6903098 (2005-06-01), Lubisch et al.
patent: 7041675 (2006-05-01), Lubisch et al.
patent: 7087637 (2006-08-01), Grandel et al.
patent: 7151102 (2006-12-01), Martin et al.
patent: 7196085 (2007-03-01), Martin et al.
patent: 7402580 (2008-07-01), Seko et al.
patent: 2004/0176361 (2004-09-01), Fujio et al.
patent: 2005/0059663 (2005-03-01), Martin et al.
patent: 2005/0080096 (2005-04-01), Ishida et al.
patent: 2005/0227919 (2005-10-01), Kudos
patent: 2006/0063767 (2006-03-01), Javaid et al.
patent: 2006/0142293 (2006-06-01), Martin et al.
patent: 2007/0093489 (2007-04-01), Javaid et al.
patent: 2008/0161280 (2008-07-01), Gandhi et al.
patent: 2008/0269234 (2008-10-01), Gandhi et al.
patent: 972755 (1975-08-01), None
patent: 2352194 (2001-04-01), None
patent: 2143745 (1973-03-01), None
patent: 3813531 (1988-04-01), None
patent: 287 032 (1991-02-01), None
patent: 0030861 (1981-06-01), None
patent: 0269968 (1988-06-01), None
patent: 0355750 (1990-02-01), None
patent: 0389995 (1990-10-01), None
patent: 0502575 (1992-09-01), None
patent: 0590551 (1994-04-01), None
patent: 0634404 (1995-01-01), None
patent: 0699754 (1996-03-01), None
patent: 0705903 (1996-04-01), None
patent: 0792643 (1997-09-01), None
patent: 1908481 (2008-04-01), None
patent: 2262513 (1975-09-01), None
patent: 721286 (1955-01-01), None
patent: 2384776 (2004-03-01), None
patent: MI98A001671 (1999-04-01), None
patent: 54156526 (1979-12-01), None
patent: 58164577 (1983-09-01), None
patent: 62-252774 (1987-11-01), None
patent: WO 91/18591 (1991-12-01), None
patent: WO 93/14086 (1993-07-01), None
patent: WO 94/10151 (1994-05-01), None
patent: WO 95/24379 (1995-09-01), None
patent: WO 96/19225 (1996-06-01), None
patent: WO 98/43477 (1998-10-01), None
patent: WO 98/51308 (1998-11-01), None
patent: WO 99/08680 (1999-02-01), None
patent: WO 99/11624 (1999-03-01), None
patent: WO 99/11645 (1999-03-01), None
patent: WO 99/11649 (1999-03-01), None
patent: WO 99/44612 (1999-09-01), None
patent: WO 99/47494 (1999-09-01), None
patent: WO 00/05219 (2000-02-01), None
patent: WO 00/42040 (2000-07-01), None
patent: WO 00/44726 (2000-08-01), None
patent: WO 00/67734 (2000-11-01), None
patent: WO 01/12199 (2001-02-01), None
patent: WO 01/16136 (2001-03-01), None
patent: WO 01/16137 (2001-03-01), None
patent: WO 01/21615 (2001-03-01), None
patent: WO 01/23390 (2001-04-01), None
patent: WO 01/57038 (2001-08-01), None
patent: WO 01/79184 (2001-10-01), None
patent: WO 01/85686 (2001-11-01), None
patent: WO 01/85687 (2001-11-01), None
patent: WO 01/87845 (2001-11-01), None
patent: WO 01/90077 (2001-11-01), None
patent: WO 02/36576 (2002-05-01), None
patent: WO 02/44157 (2002-06-01), None
patent: WO 02/068407 (2002-09-01), None
patent: WO 02/090334 (2002-11-01), None
patent: WO 02/094790 (2002-11-01), None
patent: WO 03/007959 (2003-01-01), None
patent: WO 03/051879 (2003-06-01), None
patent: WO 03/055865 (2003-07-01), None
patent: WO 03/057145 (2003-07-01), None
patent: WO 03/063874 (2003-08-01), None
patent: WO 03/070707 (2003-08-01), None
patent: WO 03/070726 (2003-08-01), None
patent: WO 03/080581 (2003-10-01), None
patent: WO 03/093261 (2003-11-01), None
patent: WO 2004/080976 (2004-09-01), None
patent: WO 2005/053662 (2005-06-01), None
patent: WO 2006/137510 (2006-12-01), None
patent: WO 2007/045877 (2007-04-01), None
patent: WO 2008/083027 (2008-07-01), None
Affar, E. B. et al., “Immunodot blot method for the detection of poly(ADP-ribose) synthesized in vitro and in vivo,” Anal. Biochem 259(2):280-283 (1998).
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology, Supplement. Archiv fur Toxikologie. Supplement, vol. 7, 219-231 (1984).
Ame, J-C. et al., “PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase,” J. Biol. Chem. 274(25):17860-17868 (1999).
Ame, J-C. et al., “The PARP superfamily,” BioEssays 26:882-893 (2004).
Angell, S.M. et al., “Consistent gene silencing in transgenic plants expressing a replicating potato virus X RNA,” EMBO J. 16(12):3675-3684 (1997).
Arnaudeau, C. et al., “DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells,” J. Mol. Biol 307:1235-1245 (2001).
Banasik, M. et al., “Inhibitors and activators of ADP-ribosylation reactions,” Mol. Cell Biochem. 138:185-197 (1994).
Banasik, M. et al., “Specific Inhibitors of Poly (ADP-Ribose) Synthetase and Mono (ADP-Ribosyl) transferse”, J. Biol. Chem., vol. 267, 1569-1575 (1992).
Ben-Hur, E. et al., “Inhibitors of poly (ADP-ribose) synthesis enhance radiation response by differentially affecting repair of potentially lethal versus sublethal damage,” Br. J. Cancer 49(VI):39-42 (1984).
Berge et al., “Pharmaceutically Acceptable Salts,” J. Pharm. Sci., vol. 66, 1-19. Protective Groups in Organic Synthesis (T. Green and P. Wuts, Wiley, 1991) (1977).
Berger, N. A. et al., “Poly (ADP-ribose) in cellular response to DNA damage”, Radiation Research, 101:4-14 (1985).
Bhattacharyya, A. et al., “The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin,” J. Biol. Chem. 275(31): 23899-23903 (2000).
Bloch, W. et al., “Poly-adenosine diphosphate-ribose polymerase inhibition for myocardial protection: pathophysiologic and physiologic considerations,” J. Thoracic Card. Surg. 128(2):323-324 (2004).
Bold, G. et al., “New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis,” J. Med. Chem. 43:3200 (Abstract) (2000).
Bold, G. et al., “New anilinophthalazines as potent and orally well absorbed inhibitors of the FEBF receptor tyrosine kinases useful as antagonists of tumour-driven angiogenesis”, J. Med. Chem., 43(12):2310-2323 (2000).
Bowman et al., “Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU 1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro,” British Journal of Cancer, 84(1):106-112 (2001).
Brummelkamp, T. R. et al., “A system for stable expression of short interfering RNAs in mammalian cells,” Science 296:550-553 (2002).
Bundgaard, H., “Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities” Desi
Barr Martin Niall Morrison
Javaid Muhammad Hashim
Menear Keith Allan
Astrazeneca AB
Kim Jennifer M
Morgan & Lewis & Bockius, LLP
Zarek Paul
LandOfFree
Phthalazinone derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phthalazinone derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phthalazinone derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2704420